GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL
July 8th 2021
Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.